Search Results
Dr. Yardley Discusses the Role of Everolimus in Breast Cancer and the BOLERO Trials
Dr. Yardley on the Role of Biosimilars in Breast Cancer
Dr. Yardley Discusses an Expanded Access Study of T-DM1 in Breast Cancer
BOLERO-2 (Afinitor and Exemestane Study) Shows Implications in ER-Positive Breast Cancer
Second-Line Everolimus in Metastatic Breast Cancer
Next Steps for Everolimus in ER-positive Metastatic Breast Cancer
Comment: BOLERO-1 reports HER2-positive breast cancer latest PFS data
Sequencing in Hormone-Driven Metastatic Breast Cancer
Emerging CDK4/6-Targeted Therapy for Breast Cancer
Dr. Yardley on Toxicities Associated With PI3K Inhibitors
Bisphosphonate Use in Breast Cancer
Dr. Tripathy on Decision-Making for Sequencing Therapies for HER2-Positive MBC